In donut hole, Medicare patients don't switch, they stop

When seniors hit the Medicare Part D donut hole, they don't switch to less expensive brands or even cheaper generics, a new Harvard Medical School/CVS Caremark study found. They stop taking meds altogether. Release

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.